| 17.49 0.13 (0.75%) | 11-11 12:06 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.3 | 1-year : | 25.77 |
| Resists | First : | 19.09 | Second : | 22.06 |
| Pivot price | 16.44 |
|||
| Supports | First : | 14.28 | Second : | 11.88 |
| MAs | MA(5) : | 16.56  |
MA(20) : | 17.29 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -1.3 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 49.3 |
D(3) : | 35.3 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 39.59 | Low : | 13.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SCTX ] has closed below upper band by 18.1%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 18.32 - 18.39 | 18.39 - 18.46 |
| Low: | 15.84 - 15.92 | 15.92 - 16 |
| Close: | 17.23 - 17.35 | 17.35 - 17.48 |
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Thu, 05 Nov 2026
Scribe Therapeutics' CEO will join a discussion in Boston, then present in New York. - Stock Titan
Thu, 05 Nov 2026
Scribe Therapeutics Inc. (SCTX) stock price, news, quote and history - Yahoo Finance Singapore
Fri, 30 Oct 2026
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Short Interest Declines 54.7% - MarketBeat
Fri, 23 Oct 2026
SCTX News | SCRIBE THERAPEUTICS INC (NASDAQ:SCTX) - ChartMill
Thu, 15 Oct 2026
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst - Seeking Alpha
Fri, 24 Jul 2026
Scribe Therapeutics: SCTX Stock Price Quote & News - Robinhood
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 20.6 (%) |
| Held by Institutions | 65.5 (%) |
| Shares Short | 1,120 (K) |
| Shares Short P.Month | 791 (K) |
| EPS | -3.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -66.34 |
| Profit Margin | -97 % |
| Operating Margin | -489.9 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -60.8 % |
| Gross Profit (p.s.) | -0.94 |
| Sales Per Share | 1.75 |
| EBITDA (p.s.) | -1.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -4.59 |
| PEG Ratio | 0 |
| Price to Book value | -0.27 |
| Price to Sales | 10 |
| Price to Cash Flow | -8.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|